Your search returned 17 results.

Results
	1.	Knowledgeable case selection results in favorable outcomes. MedStar authors: Sugarbaker, Paul H PMID: 33970169 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S30-S31, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-09 Add to cart (remove)
	2.	Ovarian cancer with peritoneal metastases has many treatment options and HIPEC is here to stay. MedStar authors: Sugarbaker, Paul H PMID: 33970163 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S189-S190, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-17 Add to cart (remove)
	3.	Adjuvant HIPEC for gastric cancer. MedStar authors: Sugarbaker, Paul H PMID: 33970159 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S18-S19, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-08 Add to cart (remove)
	4.	The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens. MedStar authors: Sugarbaker, Paul H PMID: 33970156 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S129-S130, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-15 Add to cart (remove)
	5.	A model for accurate histopathologic assessment refines treatment options. MedStar authors: Sugarbaker, Paul H PMID: 33970168 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S230, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-20 Add to cart (remove)
	6.	Super-responders to bidirectional neoadjuvant chemotherapy showed prolonged survival. MedStar authors: Sugarbaker, Paul H PMID: 33970162 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S57-S58, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-11 Add to cart (remove)
	7.	Current data is sufficient to recommend a current standard of care. MedStar authors: Sugarbaker, Paul H PMID: 33970154 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S45-S46, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-10 Add to cart (remove)
	8.	Peritoneal progression after pancreaticoduodenectomy is a devastating surgical treatment failure: HIPEC gemcitabine is an option. MedStar authors: Sugarbaker, Paul H PMID: 33970167 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S118-S119, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-14 Add to cart (remove)
	9.	Cashin and Graf: long-term intraperitoneal 5-fluorouracil is superior to adjuvant FOLFOX in a randomized trial. MedStar authors: Sugarbaker, Paul H PMID: 33970155 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S136, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-16 Add to cart (remove)
	10.	The options are neoadjuvant, adjuvant, or no chemotherapy at all: further data is needed. MedStar authors: Sugarbaker, Paul H PMID: 33970152 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S214-S215, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-19 Add to cart (remove)
	11.	Avoiding a throwback to the past. MedStar authors: Sugarbaker, Paul H PMID: 23269997 Year: 2013 Citation: Journal of Clinical Oncology. 31(3):396-7, 2013 Jan 20. Institution: MedStar Washington Hospital Center Department: Surgery/General Surgery Medline publication type: Comment Letter Form of publication: Journal Article All authors: Sugarbaker PH DOI: http://dx.doi.org/10.1200/JCO.2012.46.0675 Add to cart (remove)
	12.	Genetic targets for cancer control are a reality. MedStar authors: Sugarbaker, Paul H PMID: 33970166 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S204-S205, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-18 Add to cart (remove)
	13.	PIPAC may work but more data is needed. MedStar authors: Sugarbaker, Paul H PMID: 33970164 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S271-S272, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-22 Add to cart (remove)
	14.	Aggressive local treatments may prolong survival but do not have curative intent. MedStar authors: Sugarbaker, Paul H PMID: 33970158 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S68-S69, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-12 Add to cart (remove)
	15.	Paclitaxel is the pharmacologic near perfect chemotherapy for peritoneal metastases. MedStar authors: Sugarbaker, Paul H PMID: 33970160 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S240-S241, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-21 Add to cart (remove)
	16.	Single institution best recommendation is HIPEC with cisplatin and docetaxel. MedStar authors: Sugarbaker, Paul H PMID: 33970157 Year: 2021 Citation: Journal of Gastrointestinal Oncology. 12(Suppl 1):S79, 2021 Apr. Institution: Washington Cancer Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Sugarbaker PH, Van der Speeten K DOI: https://dx.doi.org/10.21037/jgo-2020-13 Add to cart (remove)
	17.	ASO Author Reflections: Normothermic Intraperitoneal Chemotherapy Long-Term for Malignant Peritoneal Mesothelioma. MedStar authors: Sugarbaker, Paul H PMID: 33909181 Year: 2021 Citation: Annals of Surgical Oncology. 28(12):7118-7119, 2021 11. Institution: Washington Cancer Institute Medline publication type: Comment Journal Article Form of publication: Journal Article All authors: Sugarbaker PH DOI: https://dx.doi.org/10.1245/s10434-021-10058-2 Add to cart (remove)

Powered by Koha